WIC
CRL icon

Woodmont Investment Counsel’s Charles River Laboratories CRL Stock Holding History

Woodmont Investment Counsel’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-805
Closed -$218K – 254
2024
Q1 		$218K Buy
+805
New +$192K 0.02% 247

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Woodmont Investment Counsel's CRL Position: Q2 2024 in Review

Woodmont Investment Counsel sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 805 shares — an estimated $218K sold.

Woodmont Investment Counsel first reported a position in CRL in Q1 2024 and held it in 1 quarter. The position peaked at $218K in Q1 2024. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Woodmont Investment Counsel reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Woodmont Investment Counsel sold 805 Charles River Laboratories shares in Q2 2024, an estimated $218K.
  • Woodmont Investment Counsel first reported a position in Charles River Laboratories in Q1 2024 and held it in 1 quarter.
  • Woodmont Investment Counsel's Charles River Laboratories position peaked at $218K in Q1 2024.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Woodmont Investment Counsel's 13F filing for Q2 2024, filed 18 Jul 2024.